Actively Recruiting
Real-world Data in Patients With Breast Cancer Treated With Abemaciclib
Led by Hellenic Cooperative Oncology Group · Updated on 2025-05-18
108
Participants Needed
1
Research Sites
299 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The present study will assess real-world clinical outcomes and adverse events from treatment with endocrine therapy combined with abemaciclib in patients with HR-positive, HER2-negative advanced breast cancer.
CONDITIONS
Official Title
Real-world Data in Patients With Breast Cancer Treated With Abemaciclib
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed hormone receptor-positive, HER2-negative breast cancer
- Treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated oncology departments
- 18 years of age or older
- Any menopausal status
- Currently receiving abemaciclib combined with endocrine therapy
- Any type of endocrine therapy allowed
- At least two months of treatment with abemaciclib
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hellenic Oncology Cooperative Group
Athens, Greece
Actively Recruiting
Research Team
E
Elena Fountzilas, MD, PhD
CONTACT
A
Areti Stamboliou
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here